Heron Therapeutics (NASDAQ:HRTX) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered shares of Heron Therapeutics (NASDAQ:HRTX - Free Report) from a buy rating to a hold rating in a research report released on Thursday.

Separately, Needham & Company LLC reiterated a "buy" rating and set a $4.00 price target on shares of Heron Therapeutics in a research report on Friday, April 11th.

Heron Therapeutics Trading Up 3.5%

Shares of HRTX traded up $0.07 during mid-day trading on Thursday, hitting $1.92. The company's stock had a trading volume of 418,854 shares, compared to its average volume of 1,717,698. Heron Therapeutics has a 1-year low of $1.04 and a 1-year high of $3.93. The firm has a market capitalization of $292.16 million, a P/E ratio of -10.64 and a beta of 1.33. The firm has a 50-day simple moving average of $2.08 and a 200 day simple moving average of $1.83.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $0.02. The business had revenue of $38.90 million during the quarter, compared to analyst estimates of $37.08 million. As a group, sell-side analysts predict that Heron Therapeutics will post -0.13 EPS for the current fiscal year.

Institutional Trading of Heron Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. grew its holdings in Heron Therapeutics by 295.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company's stock valued at $411,000 after buying an additional 154,487 shares during the last quarter. Arkadios Wealth Advisors acquired a new stake in shares of Heron Therapeutics during the fourth quarter valued at $76,000. Capital Planning Advisors LLC increased its position in Heron Therapeutics by 41.0% during the 4th quarter. Capital Planning Advisors LLC now owns 106,565 shares of the biotechnology company's stock worth $163,000 after purchasing an additional 31,003 shares in the last quarter. Apeiron RIA LLC raised its stake in Heron Therapeutics by 7.8% in the 4th quarter. Apeiron RIA LLC now owns 262,542 shares of the biotechnology company's stock valued at $402,000 after purchasing an additional 19,000 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in Heron Therapeutics by 10.6% in the 4th quarter. Principal Financial Group Inc. now owns 113,560 shares of the biotechnology company's stock valued at $174,000 after purchasing an additional 10,909 shares during the last quarter. Hedge funds and other institutional investors own 80.01% of the company's stock.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.